Matthew Galsky Gives an Overview of Bladder Cancer

Padcev plus Keytruda may improve survival outcomes for some patients with advanced urothelial cancer, according to preliminary data.

“I treat all of my patients like my friends and family,” said Dr. Ravi Munver of Hackensack University Medical Center, who first met Peter Kahan as his honors physics teacher more than 35 years ago.

Patients with nonmetastatic node-positive bladder cancer may have similar survival rates whether they underwent treatment with surgery or radical dose radiotherapy.

In this episode of the “CURE® Talks Cancer” podcast, a cancer survivor who served in the Vietnam War shares the story of his Agent Orange exposure and bladder cancer.

Findings from the phase 3 ATLAS and ENVISION trials reveal a non-surgical way to possibly benefit patients with low-grade, intermediate- risk non-muscle invasive bladder cancer.

A phase 1 trial just launched, and will evaluate IO102-IO103 plus Keytruda in patients with bladder cancer whose disease is unresponsive to BCG therapy.